LYEL · Categories · Form 4

LYEL - SEC Form 4 insider transactions

Lyell Immunopharma Inc. (LYEL) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for LYEL

• 79d
  SEC Form 4 filed by Chief Fin. and Bus. Officer Shah Smital

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 111d
  President and CEO Seely Lynn sold $174,372 worth of shares (7,455 units at $23.39), decreasing direct ownership by 9% to 74,266 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 111d
  Chief Operating Officer Hill Stephen J. sold $28,910 worth of shares (1,236 units at $23.39), decreasing direct ownership by 6% to 17,795 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 111d
  Chief Scientific Officer Lee Gary K. sold $39,085 worth of shares (1,671 units at $23.39), decreasing direct ownership by 9% to 16,938 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 112d
  Chief Operating Officer Hill Stephen J. was granted 4,000 shares and sold $2,520 worth of shares (109 units at $23.12), increasing direct ownership by 26% to 19,031 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 112d
  Chief Scientific Officer Lee Gary K. was granted 4,000 shares and sold $3,399 worth of shares (147 units at $23.12), increasing direct ownership by 26% to 18,609 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 112d
  President and CEO Seely Lynn was granted 20,000 shares and sold $10,127 worth of shares (438 units at $23.12), increasing direct ownership by 31% to 81,721 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 112d
  SEC Form 4 filed by General Counsel Meltz Mark A

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 112d
  VP, Corporate Controller Bulis Veronica Sanchez was granted 8,750 shares and sold $5,872 worth of shares (254 units at $23.12), increasing direct ownership by 119% to 15,637 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 112d
  SEC Form 4 filed by Chief Medical Officer Shook David

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 148d
  VP, Corporate Controller Bulis Veronica Sanchez sold $74,181 worth of shares (2,072 units at $35.80), decreasing direct ownership by 22% to 7,141 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 203d
  President and CEO Seely Lynn sold $6,637 worth of shares (412 units at $16.11), decreasing direct ownership by 0.61% to 67,159 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 203d
  VP, Corporate Controller Bulis Veronica Sanchez sold $3,848 worth of shares (239 units at $16.10), decreasing direct ownership by 3% to 9,213 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 203d
  Chief Scientific Officer Lee Gary K. sold $2,230 worth of shares (138 units at $16.16), decreasing direct ownership by 0.89% to 15,366 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 203d
  Chief Operating Officer Hill Stephen J. sold $1,531 worth of shares (95 units at $16.12), decreasing direct ownership by 0.60% to 15,750 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 217d
  SEC Form 4 filed by Chief Operating Officer Hill Stephen J.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 217d
  SEC Form 4 filed by Chief Scientific Officer Lee Gary K.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 217d
  SEC Form 4 filed by President and CEO Seely Lynn

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 285d
  President and CEO Seely Lynn was granted 40,000 shares and sold $76,518 worth of shares (7,257 units at $10.54), increasing direct ownership by 94% to 67,571 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 285d
  Chief Operating Officer Hill Stephen J. was granted 8,000 shares and sold $10,586 worth of shares (1,004 units at $10.54), increasing direct ownership by 79% to 15,845 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 285d
  Chief Financial Officer Newton Charles W. was granted 8,000 shares and sold $15,320 worth of shares (1,453 units at $10.54), increasing direct ownership by 75% to 15,306 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 285d
  Chief Scientific Officer Lee Gary K. was granted 8,000 shares and sold $15,320 worth of shares (1,453 units at $10.54), increasing direct ownership by 73% to 15,504 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 294d
  President and CEO Seely Lynn sold $8,313 worth of shares (797 units at $10.43), decreasing direct ownership by 2% to 34,828 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 294d
  Chief Operating Officer Hill Stephen J. sold $1,930 worth of shares (185 units at $10.43), decreasing direct ownership by 2% to 8,849 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 294d
  Chief Scientific Officer Lee Gary K. sold $2,785 worth of shares (267 units at $10.43), decreasing direct ownership by 3% to 8,957 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 294d
  Chief Financial Officer Newton Charles W. sold $2,785 worth of shares (267 units at $10.43), decreasing direct ownership by 3% to 8,759 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 309d
  SEC Form 4 filed by Large owner Arch Venture Partners Ix, Llc

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 357d
  SEC Form 4 filed by Director Bachleda Mark

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 357d
  SEC Form 4 filed by General Counsel Meltz Mark A

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 357d
  Chief Medical Officer Shook David was granted 21,900 shares (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 380d
  SEC Form 4 filed by Director Klausner Richard

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 380d
  SEC Form 4 filed by Director Rieflin William Jl

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 380d
  SEC Form 4 filed by Director Friedman Cathy

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 380d
  SEC Form 4 filed by Director Brawley Otis W

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 380d
  SEC Form 4 filed by Director Nabel Elizabeth G

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 380d
  SEC Form 4 filed by Director Ramachandra Sumant

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 462d
  Chief Business Officer Lang Matthew was granted 112,500 shares, increasing direct ownership by 225% to 162,500 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 462d
  President and CEO Seely Lynn was granted 337,500 shares, increasing direct ownership by 169% to 537,500 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 462d
  Chief Operating Officer Hill Stephen J. was granted 112,500 shares, increasing direct ownership by 186% to 172,899 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 462d
  Chief Financial Officer Newton Charles W. was granted 112,500 shares, increasing direct ownership by 187% to 172,725 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 462d
  Chief Scientific Officer Lee Gary K. was granted 112,500 shares, increasing direct ownership by 175% to 176,696 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 579d
  SEC Form 4 filed by Director Ramachandra Sumant

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Nelsen Robert

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Bishop Hans Edgar

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Klausner Richard

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Rieflin William Jl

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Nabel Elizabeth G

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Brawley Otis W

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 716d
  SEC Form 4 filed by Director Friedman Cathy

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 841d
  Lang Matthew was granted 50,000 shares (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 841d
  Hill Stephen J. was granted 40,000 shares, increasing direct ownership by 448% to 48,928 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 841d
  Lee Gary K. was granted 40,000 shares, increasing direct ownership by 315% to 52,700 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 841d
  Newton Charles W. was granted 40,000 shares, increasing direct ownership by 458% to 48,729 units (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 841d
  Seely Lynn was granted 200,000 shares (SEC Form 4)

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 926d
  SEC Form 4 filed by Newton Charles W.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 926d
  SEC Form 4 filed by Lee Gary K.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 926d
  SEC Form 4 filed by Seely Lynn

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 926d
  SEC Form 4 filed by Hill Stephen J.

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 999d
  SEC Form 4 filed by Klausner Richard

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
• 999d
  SEC Form 4 filed by Rieflin William Jl

  4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

Other LYEL categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends